Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,”…
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,”…
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,”…
BASKING RIDGE, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
BASKING RIDGE, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage…
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage…
Glen Rock, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI)…
Glen Rock, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI)…
Bagsværd, Denmark, 1 February 2023 – Novo Nordisk A/S has filed its Annual Report 2022…
Bagsværd, Denmark, 1 February 2023 – Novo Nordisk A/S has filed its Annual Report 2022…
FDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study New Publication Supports Eventual Pursuit…
FDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study New Publication Supports Eventual Pursuit…
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) — Recludix Pharma, a leader in platform approaches…
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) — Recludix Pharma, a leader in platform approaches…
REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage…
REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage…
Agreement builds upon the existing relationship with WuXi XDC for CMC development and GMP manufacturing…
Agreement builds upon the existing relationship with WuXi XDC for CMC development and GMP manufacturing…